Is Sana Biotechnology, Inc. (SANA) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 11.2% / 30% | 18.2% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 11.2% / 33% | 18.2% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 18.8% / 33% | 30.4% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| S&P | 11.2% / 33% | 18.2% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 18.8% / 33% | 30.4% / 33% | 0.0% / 50% | N/A | ✓ HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -118.7% | |
| Return on Assets (ROA) | -26.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$144M |
| Free Cash Flow | -$145M |
| Total Debt | $79M |
| Debt-to-Equity | 53.6 |
| Current Ratio | 1.9 |
| Total Assets | $417M |
Price & Trading
| Last Close | $3.03 |
| 50-Day MA | $3.89 |
| 200-Day MA | $3.94 |
| Avg Volume | 2.5M |
| Beta | 2.0 |
|
52-Week Range
$1.26
| |
About Sana Biotechnology, Inc. (SANA)
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therapy, which is in preclinical trial for the treatment of type 1 diabetes; SG293 and SG299, a CD8-targeted fusosome for the treatment of B cell hematologic malignancies and B cell mediated autoimmune diseases. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Sana Biotechnology, Inc. (SANA) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Sana Biotechnology, Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Sana Biotechnology, Inc.'s debt ratio?
Sana Biotechnology, Inc.'s debt ratio is 11.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 18.8%.
What are Sana Biotechnology, Inc.'s key financial metrics?
Sana Biotechnology, Inc. has a market capitalization of $739M. Return on equity stands at -118.7%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.